ホーム>>Signaling Pathways>> Others>>24-Norursodeoxycholic acid (nor-UDCA)

24-Norursodeoxycholic acid (nor-UDCA) (Synonyms: norUDCA, 24-Norursodeoxycholic Acid, Nourcholic Acid)

カタログ番号GC33867

24-ノルルソデオキシコール酸 (ノルコール酸) は、UDCA の側鎖が短縮された C23 同族体であり、強力な抗胆汁うっ滞性、抗炎症性、抗線維性を示しています。

Products are for research use only. Not for human use. We do not sell to patients.

24-Norursodeoxycholic acid (nor-UDCA) 化学構造

Cas No.: 99697-24-2

サイズ 価格 在庫数 個数
1mg
$29.00
在庫あり
5mg
$63.00
在庫あり
10mg
$99.00
在庫あり
20mg
$174.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product has been cited by 1 publications

Description Chemical Properties Product Documents Related Products

24-norursodeoxycholic acid (norUDCA) is a side chain-shortened C23 homologue of UDCA and has shown potent anti-cholestatic, anti-inflammatory and anti-fibrotic properties.

24-norursodeoxycholic acid (norUDCA) is a side chain-shortened C23 homologue of UDCA and is previously shown to be highly effective in preclinical mouse models of cholestatic and fibrotic liver diseases. 24-norursodeoxycholic acid significantly reduces serum alkaline phosphatase (ALP) levels in a dose-dependent fashion. 24-norursodeoxycholic acid also significantly reduces γ-GT, ALT, and AST serum levels[1].

[1]. Fickert P, et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology. 2006 Feb;130(2):465-81.

レビュー

Review for 24-Norursodeoxycholic acid (nor-UDCA)

Average Rating: 5 ★★★★★ (Based on Reviews and 32 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 24-Norursodeoxycholic acid (nor-UDCA)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.